Short answer: Most scaling life sciences companies are better served by a single primary cloud, designed across multiple regions and paired with the on-premises systems their labs and manufacturing sites need. A multi-vendor or multi-cloud setup is the right call when a specific requirement demands it: acquired systems, a tool only available on another provider, or a partner or regulatory mandate. The decision should rest on five factors: compliance scope, data gravity, security surface, operating cost, and team capacity.
As life sciences companies grow into commercial operations, infrastructure decisions get harder to reverse. New sites come online, acquisitions bring their own systems, and partners ask for data in their own environments. The question stops being “which cloud?” and becomes “how many, and why?” The answer affects cost, compliance, and security for years.
What is the difference between multi-vendor, multi-cloud, and single-cloud infrastructure?
Single-cloud infrastructure runs a company’s cloud workloads on one public cloud provider. Multi-cloud uses two or more public cloud providers. Multi-vendor is broader: it describes infrastructure spread across several cloud, hosting, software, and service providers, often with separate vendors for security, networking, and support.
Most life sciences companies are also hybrid, meaning some systems stay on-premises. Instruments, manufacturing execution systems, and lab equipment often have to stay on-site. Hybrid is usually a necessity. Multi-cloud and multi-vendor are choices, and they should be made on purpose.
What factors should drive the infrastructure decision as a life sciences company scales?
Five factors should drive the decision: compliance scope, data gravity, security surface, total operating cost, and team capacity. Each factor should be weighed against concrete business requirements, not general preferences such as “flexibility” or “avoiding lock-in.”
Here’s how to apply them, in order:
- Compliance scope: count how many environments will hold GxP-regulated data. Each one needs its own validation, audit trails, and change control under 21 CFR Part 11.
- Data gravity: find where the largest scientific datasets live. Moving terabytes between providers is slow and costly, so compute should generally run where the data is.
- Security surface: count the identity systems, logging tools, and security models the team will need to monitor around the clock.
- Total operating cost: add up engineers, tooling, training, validation effort, and data transfer, not just compute and storage.
- Team capacity: check whether the internal team or partner can realistically run more than one environment well.
When is single-cloud the better choice for a life sciences company?
Single-cloud is the better choice when no specific requirement demands a second provider. For most scaling life sciences companies, one primary cloud with multi-region design delivers strong resilience, simpler GxP validation, a smaller security surface, and deeper expertise from the team running it.
Going deep on one platform also unlocks more of what that platform offers: purpose-built services for genomics and AI, partner programs and funding, and architecture patterns engineers have deployed many times. Breadth across clouds tends to trade that depth for coordination work.
When is multi-cloud or multi-vendor the better choice?
Multi-cloud or multi-vendor is the better choice when a concrete requirement calls for it. The most common triggers are an acquisition that brings validated systems on another cloud, a scientific tool or dataset only available on another provider, a partner or CRO requirement, or a data residency rule the primary cloud can’t meet.
Even then, the best practice is tight scoping. Keep the secondary environment limited to the workload that needs it, and manage security, identity, monitoring, and cost reporting centrally, so the second environment doesn’t become a separate silo.
How much does multi-cloud add to operating costs?
Multi-cloud adds operating cost mainly through duplicated tooling, additional trained engineers, separate compliance documentation, and data transfer fees between providers. Compute and storage prices may look comparable, but running two environments well takes more people and more process.
Data transfer is the cost that scaling companies most often underestimate. Cloud providers generally charge per GB for data leaving their network once a small monthly allowance is used up. AWS, for example, includes 100 GB of free data transfer out to the internet each month (AWS EC2 pricing). At scientific data volumes, that allowance runs out quickly.
How does the choice affect GxP compliance?
Each additional environment holding regulated data adds GxP validation, change control, and audit scope. A single primary cloud concentrates that work in one validated environment. A multi-cloud setup requires validated configurations, audit trails, and documented data flows across every provider involved.
Auditors will also ask how regulated data moves between environments. In a multi-cloud setup, the chain of custody for a dataset that starts on one provider and ends on another has to be fully documented and verifiable.
How should a company handle multiple clouds inherited through an acquisition?
A company should handle clouds inherited through an acquisition by mapping every workload to its business purpose, then deciding whether it should stay, move, or be retired. Validated manufacturing or clinical systems often stay in place short term, with migration planned in phases to avoid disrupting operations.
Integration of security monitoring, identity, and cost reporting should happen right away, even if workloads stay where they are. That way, the acquired environment is visible and governed from the first day, not months later.
Single-Cloud vs. Multi-Cloud for Scaling Life Sciences Companies
| Factor | Single primary cloud | Multi-cloud / multi-vendor |
|---|---|---|
| GxP validation scope | One environment to validate and maintain | Every provider holding regulated data |
| Security surface | One identity and logging model | Multiple models to monitor and reconcile |
| Data transfer costs | Mostly within one provider | Fees between providers at terabyte scale |
| Platform depth | Deep use of purpose-built services and programs | Shallower use spread across platforms |
| Resilience | Multi-region design within one provider | Cross-provider, with more complexity |
| Best fit | Most scaling companies without a specific mandate | Acquisitions, specialized tools, partner or residency requirements |
What do life sciences companies get wrong about multi-vendor and single-cloud decisions?
The most common mistake is drifting into multi-cloud without deciding to. Individual teams start projects on different providers, acquisitions add more, and the company ends up with several environments no one designed together. A second mistake is choosing multi-cloud to avoid lock-in without pricing what it costs to run.
Companies also get single-cloud wrong, usually by treating it as a reason to skip portability. Containerized pipelines, infrastructure as code, and open data formats keep switching costs manageable, even on one provider. A third mistake is separating the cloud decision from the vendor decision. Four vendors managing security, networking, cloud, and support create the same gaps multi-cloud does.
The data behind infrastructure strategy decisions
Hybrid is the norm: 73% of organizations operate hybrid environments, up three percentage points year over year (Flexera 2026 State of the Cloud Report, March 2026).
Waste grows with complexity: organizations estimate 29% of IaaS and PaaS spend is wasted, the first increase in five years (Flexera, March 2026).
Security leads the concern list: 53% of cloud leaders cite security and compliance as their top challenge for cloud-based AI initiatives, per the same Flexera report.
FAQ
Can a company start single-cloud and add a second provider later?
Yes. Starting on one primary cloud with portable pipelines and infrastructure as code keeps that option open. A second provider can be added later for a specific workload, with governance extended to cover it.
Does multi-cloud improve negotiating leverage with cloud providers?
Sometimes, but rarely enough to offset the operating overhead of running two environments. Committed-use agreements, partner programs, and cost optimization within one provider often deliver more savings with less complexity.
How does a hybrid setup fit into this decision?
Hybrid is usually a given in life sciences, because instruments and manufacturing systems stay on-site. The decision is how many public clouds to connect to that on-premises footprint. For most companies the answer is one, managed alongside on-premises systems as a single environment.
Who should own the infrastructure strategy decision?
Typically the head of IT or CIO, with input from quality, security, finance, and research leadership. The decision touches validation, budget, and scientific workflows, so it shouldn’t be made by one team in isolation.
Related reading
- Ask Our Cloud Architects: Is Multi-Cloud Right for Your Life Sciences Company?
- The Hidden Cost of IT Silos (and Why We Refuse to Have Them)
- What Does an AWS Partnership Actually Deliver for a Biotech’s Cloud Infrastructure?
- How Should a Biotech Architect Cloud Infrastructure for Genomics, Imaging, and Big Data?
- Why Life Sciences Needs a Purpose-Built IT Partner (Not Just Another MSP)
Not sure whether your current setup is intentional or accidental? Get an infrastructure strategy assessment → Contact Us.